Comparative Pharmacology
Head-to-head clinical analysis: FERNISOLONE P versus FLORONE E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERNISOLONE P versus FLORONE E.
FERNISOLONE-P vs FLORONE E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment
Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile.
Category C
Category C
Corticosteroid
Corticosteroid